With one pan­dem­ic still rag­ing, J&J bets $780M on a po­ten­tial flu ther­a­py for the next

As it rolls out the first jabs of its Covid-19 vac­cine in the US, J&J al­ready has its eyes on the next pan­dem­ic. Now, it’s will­ing to bet up to $780 mil­lion on a new class of drugs that Cidara Ther­a­peu­tics says could take out all strains of the flu.

Janssen, J&J’s Bel­gian sub­sidiary, is plunk­ing down $27 mil­lion up­front for ac­cess to Cidara’s lead an­tivi­ral con­ju­gate CD388, which CEO Jef­frey Stein says has the po­ten­tial to treat and pro­tect against all flu strains with a sin­gle dose. The deal is one ex­am­ple of the next wave of pipeline work be­ing es­tab­lished as the US be­gins to get its hands around the cur­rent pan­dem­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA